Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Armed Exosomes Deliver Proapoptotic Signals to Tumor Site.

Rivoltini L, Chiodoni C, Squarcina P, Tortoreto M, Villa A, Vergani B, B├╝rdek M, Botti L, Arioli I, Cova A, Mauri G, Vergani E, Bianchi B, Della Mina P, Cantone L, Bollati V, Zaffaroni N, Gianni AM, Colombo MP, Huber V.

Clin Cancer Res. 2016 Jul 15;22(14):3499-512. doi: 10.1158/1078-0432.CCR-15-2170. Epub 2016 Mar 4.


Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.

Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion-Sileni V, Villa A, Lombardo C, Tragni G, Santinami M, Parmiani G, Rivoltini L.

Clin Cancer Res. 2012 Dec 1;18(23):6485-96. doi: 10.1158/1078-0432.CCR-12-1516. Epub 2012 Oct 2.


Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide.

Iero M, Squarcina P, Romero P, Guillaume P, Scarselli E, Cerino R, Carrabba M, Toutirais O, Parmiani G, Rivoltini L.

Cancer Immunol Immunother. 2007 Dec;56(12):1979-91. Epub 2007 Jun 13.


Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.

Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, Zaccheddu A, Colone M, Arancia G, Gentile M, Seregni E, Valenti R, Ballabio G, Belli F, Leo E, Parmiani G, Rivoltini L.

Gastroenterology. 2005 Jun;128(7):1796-804.


Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.

Pilla L, Squarcina P, Coppa J, Mazzaferro V, Huber V, Pende D, Maccalli C, Sovena G, Mariani L, Castelli C, Parmiani G, Rivoltini L.

Cancer Res. 2005 May 1;65(9):3942-9.


Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.

Rivoltini L, Castelli C, Carrabba M, Mazzaferro V, Pilla L, Huber V, Coppa J, Gallino G, Scheibenbogen C, Squarcina P, Cova A, Camerini R, Lewis JJ, Srivastava PK, Parmiani G.

J Immunol. 2003 Oct 1;171(7):3467-74.


Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.

Novellino L, Renkvist N, Rini F, Mazzocchi A, Rivoltini L, Greco A, Deho P, Squarcina P, Robbins PF, Parmiani G, Castelli C.

J Immunol. 2003 Jun 15;170(12):6363-70.


Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.

Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L.

Cancer Res. 2003 Apr 1;63(7):1560-7.


Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.

Lozupone F, Rivoltini L, Luciani F, Venditti M, Lugini L, Cova A, Squarcina P, Parmiani G, Belardelli F, Fais S.

Eur J Immunol. 2003 Feb;33(2):556-66.


Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.

Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, Stringaro A, Molinari A, Arancia G, Gentile M, Parmiani G, Fais S.

J Exp Med. 2002 May 20;195(10):1303-16.


A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.

Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, Rini F, Viggiano V, Belli F, Parmiani G.

Cancer Res. 1999 Jan 15;59(2):301-6.


Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.

Rivoltini L, Radrizzani M, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Colombo MP, Parmiani G.

J Immunol. 1998 Aug 1;161(3):1220-30.


Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).

Loftus DJ, Squarcina P, Nielsen MB, Geisler C, Castelli C, Odum N, Appella E, Parmiani G, Rivoltini L.

Cancer Res. 1998 Jun 1;58(11):2433-9.


Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.

Rivoltini L, Loftus DJ, Squarcina P, Castelli C, Rini F, Arienti F, Belli F, Marincola FM, Geisler C, Borsatti A, Appella E, Parmiani G.

Crit Rev Immunol. 1998;18(1-2):55-63. Review.


Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).

Loftus DJ, Castelli C, Clay TM, Squarcina P, Marincola FM, Nishimura MI, Parmiani G, Appella E, Rivoltini L.

J Exp Med. 1996 Aug 1;184(2):647-57.


Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.

Anichini A, Mortarini R, Maccalli C, Squarcina P, Fleischhauer K, Mascheroni L, Parmiani G.

J Immunol. 1996 Jan 1;156(1):208-17.


Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.

Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G.

J Exp Med. 1993 Apr 1;177(4):989-98.


Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma.

Fossati G, Anichini A, Squarcina P, Mazzocchi A, Parmiani G.

Int J Cancer. 1988 Aug 15;42(2):239-45.


Reactivity of human lymphocyte clones to autologous metastatic melanoma cells.

Fossati G, Anichini A, Mazzocchi A, Squarcina P, Parmiani G.

Adv Exp Med Biol. 1988;233:73-80. No abstract available.


Supplemental Content

Loading ...
Support Center